Future brain therapies for Parkinson's possible with stem cell bioengineering innovation
News Mar 18, 2016
Scientists develop novel way to inject healthy human nerve cells into the brain -
Scientists at Rutgers and Stanford universities have created a new technology that could someday help treat Parkinson’s disease and other devastating brain-related conditions that affect millions of people.
The technology – a major innovation – involves converting adult tissue-derived stem cells into human neurons on 3-D “scaffolds,” or tiny islands, of fibers, said Prabhas V. Moghe, a distinguished professor in the departments of Biomedical Engineering and Chemical and Biochemical Engineering at Rutgers University.
See Also: Growing functioning brain tissue in 3D
The scaffolds, loaded with healthy, beneficial neurons that can replace diseased cells, were injected into mouse brains.
“If you can transplant cells in a way that mimics how these cells are already configured in the brain, then you’re one step closer to getting the brain to communicate with the cells that you're now transplanting,” said Moghe, research director for the School of Engineering/Health Sciences Partnerships at Rutgers. “In this work, we’ve done that by providing cues for neurons to rapidly network in 3-D.”
In their multidisciplinary study, published in Nature Communications, a dozen scientists from several Rutgers teams and Stanford discuss the 3-D scaffolds and their potentially widespread benefits.
Moghe said a 3-D scaffold, developed by the scientists, consists of tiny polymer fibers. Hundreds of neurons attach to the fibers and branch out, sending their signals. Scaffolds are about 100 micrometers wide – roughly the width of a human hair.
“We take a whole bunch of these islands and then we inject them into the brain of the mouse,” he said. “These neurons that are transplanted into the brain actually survived quite miraculously well. In fact, they survived so much better than the gold standard in the field.”
Indeed, the scaffold technology results in a 100-fold increase in cell survival over other methods, Moghe said.
And that may eventually help people suffering from Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, spinal cord and traumatic brain injuries, and concussions, he said, as these diseases and conditions often arise from the loss of brain cells.
Learn More: An accessible approach to making a mini-brain
The next step would be to further improve the scaffold biomaterials, allowing scientists to increase the number of implanted neurons in the brain. “The more neurons we can transplant, the more therapeutic benefits you can bring to the disease,” Moghe said. “We want to try to stuff as many neurons as we can in as little space as we can.”
The idea is to “create a very dense circuitry of neurons that is not only highly functioning but also better controlled,” he said, adding that testing of mice with Parkinson’s disease is underway to see if they improve or recover from the illness.
Eventually, with continued progress, the researchers could perform studies in people. Moghe estimated that it would take 10 to 20 years to test the technology in humans.
Developing the scaffold technology and reprogramming the stem cells in the scaffolds was “very hard team work,” he said. “It took many years to get here, so there was a lot of sweat and toil.”
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Carlson AL et al. Generation and transplantation of reprogrammed human neurons in the brain using 3D microtopographic scaffolds. Nature Communications, Published March 17 2016. doi: 10.1038/ncomms10862
Therapeutic Avenue for Parkinson's Disease?News
A new potential therapeutic avenue for Parkinson's disease. This research is unusual given that it focuses on senescence in astrocytes, so called "helper" cells that perform a variety of tasks, from axon guidance and synaptic support to control of the blood brain barrier and blood flow.READ MORE
Using Epigenetic Signatures and Machine Learning to Improve DiagnosisNews
Unique epigenetic signatures for nine neurodevelopmental disorders have been identified, lending to a better method of diagnosis for disorders with much clinical overlap.READ MORE
Valence Mapped: Brain study reveals roots of desire and dislike in the amygdalaNews
Researchers map the amygdala's distinct but diverse and dynamic neighbourhoods where feelings are assigned.READ MORE